Employees: 03 (2023.0)Legal category: 5485Size: PMECreation date: 2018-09-17 (7 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: VALENCE (26000), Drome
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
SELARL GRANDE PHARMACIE DANTON : revenue, balance sheet and financial ratios
SELARL GRANDE PHARMACIE DANTON is a French company
founded 7 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in VALENCE (26000),
this company of category PME
shows in 2022 a revenue of 1.9 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - SELARL GRANDE PHARMACIE DANTON (SIREN 842432668)
Indicator
2024
2023
2022
2021
2020
2019
Revenue
N/C
N/C
1 928 106 €
N/C
N/C
N/C
Net income
81 551 €
84 418 €
111 461 €
69 114 €
63 820 €
14 174 €
EBITDA
N/C
N/C
174 908 €
N/C
N/C
N/C
Net margin
N/C
N/C
5.8%
N/C
N/C
N/C
Revenue and income statement
In 2024, SELARL GRANDE PHARMACIE DANTON generates positive net income of 82 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2019-2024: 14 k€ -> 82 k€.
Net income (2024)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
81 551 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 109%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 38%. The balance between equity and debt is satisfactory.
Debt ratio (2024)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
109.214%
Financial autonomy (2024)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
37.87%
Asset age ratio (2024)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Solvency indicators evolution SELARL GRANDE PHARMACIE DANTON
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2019
2020
2021
2022
2023
2024
Debt ratio
758.432
468.377
304.861
212.673
151.435
109.214
Financial autonomy
10.415
14.085
19.662
25.315
30.605
37.87
Repayment capacity
None
None
None
4.841
None
None
Cash flow / Revenue
None%
None%
None%
6.985%
None%
None%
Sector positioning
Debt ratio
109.212024
2022
2023
2024
Q1: 16.46
Med: 58.48
Q3: 154.77
Average-12 pts over 3 years
In 2024, the debt ratio of SELARL GRANDE PHARMACIE D... (109.21) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
Financial autonomy
37.87%2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Average+11 pts over 3 years
In 2024, the financial autonomy of SELARL GRANDE PHARMACIE D... (37.9%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
Repayment capacity
4.84 years2022
2022
Q1: 1.29 years
Med: 3.55 years
Q3: 6.63 years
Average
In 2022, the repayment capacity of SELARL GRANDE PHARMACIE D... (4.84) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 128.27. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2024)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
128.271
Liquidity indicators evolution SELARL GRANDE PHARMACIE DANTON
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2019
2020
2021
2022
2023
2024
Liquidity ratio
140.429
147.998
154.24
146.544
138.276
128.271
Interest coverage
None
None
None
3.467
None
None
Sector positioning
Liquidity ratio
128.272024
2022
2023
2024
Q1: 129.46
Med: 182.14
Q3: 260.79
Watch
In 2024, the liquidity ratio of SELARL GRANDE PHARMACIE D... (128.27) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.
Interest coverage
3.47x2022
2022
Q1: 0.75x
Med: 2.51x
Q3: 5.16x
Good
In 2022, the interest coverage of SELARL GRANDE PHARMACIE D... (3.5x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2024)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2024)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2024)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2024)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution SELARL GRANDE PHARMACIE DANTON
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2019
2020
2021
2022
2023
2024
Operating WCR
0 €
0 €
0 €
193 273 €
0 €
0 €
Inventory turnover (days)
0
0
0
29
0
0
Customer payment term (days)
0
0
0
3
0
0
Supplier payment term (days)
0
0
0
48
0
0
Positioning of SELARL GRANDE PHARMACIE DANTON in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 225 transactions of similar company sales
in 2024,
the value of SELARL GRANDE PHARMACIE DANTON is estimated at
1 138 512 €
(range 792 841€ - 1 703 279€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2024
225 transactions
792k€1138k€1703k€
1 138 512 €Range: 792 841€ - 1 703 279€
NAF 5 année 2024
Valuation method used
Net Income Multiple
81 551 €
×
14.0x
=1 138 512 €
Range: 792 842€ - 1 703 279€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare SELARL GRANDE PHARMACIE DANTON with other companies in the same sector:
Frequently asked questions about SELARL GRANDE PHARMACIE DANTON
What is the revenue of SELARL GRANDE PHARMACIE DANTON ?
The revenue of SELARL GRANDE PHARMACIE DANTON in 2022 is 1.9 M€.
Is SELARL GRANDE PHARMACIE DANTON profitable?
Yes, SELARL GRANDE PHARMACIE DANTON generated a net profit of 82 k€ in 2024.
Where is the headquarters of SELARL GRANDE PHARMACIE DANTON ?
The headquarters of SELARL GRANDE PHARMACIE DANTON is located in VALENCE (26000), in the department Drome.
Where to find the tax return of SELARL GRANDE PHARMACIE DANTON ?
The tax return of SELARL GRANDE PHARMACIE DANTON is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does SELARL GRANDE PHARMACIE DANTON operate?
SELARL GRANDE PHARMACIE DANTON operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart